1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
EastWest Bioscience Inc.

EastWest Bioscience Inc.

HBOSF
EastWest Bioscience Inc.US flagOther OTC
0.00
USD
- -
- -
7,780.00Market Cap
EastWest Bioscience Inc.
HBOSF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
TTM
FRC
- -
- -
- -
- -
0.02
0.01
0.01
- -
Revenue per Share
-0.01
-0.02
-0.04
-0.06
-0.05
-0.01
-0.02
- -
Basic EPS, GAAP
-0.02
-0.02
-0.02
-0.06
-0.03
- -
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.01
-0.03
-0.05
0.05
- -
-0.01
-0.01
0.03
Book Value per Share
0.04
0.02
0.05
0.05
0.01
- -
- -
0.03
Tangible Book Value per Share
2
2
6
53
79
84
95
99
Basic Weighted Avg Shares
- -
- -
- -
- -
1
1
1
- -
Sales/Revenue/Turnover
- -
- -
- -
-2,237.17
-208.8
-151.49
-205.59
-674.22
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
-3
-4
-1
-2
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-2,538.98
-262.49
-122.68
-256.23
37.23
Profit Margin (%)
- -
- -
- -
1
-2
-2
-2
-3
Working Capital
- -
- -
- -
1
- -
- -
- -
- -
LT Debt
- -
- -
- -
3
1
- -
- -
3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
25.44
Return on Capital (%)
- -
- -
- -
- -
-282.62
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Oct'22
Jan'22
Apr'22
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
98
101
101
Market Capitalization
- -
2
- -

Working Capital

FRC

•

in mil. unless spec.
Oct'22
Jan'22
Apr'22
Total Current Assets
1
- -
- -
Cash, Cash Equivalents & STI
1
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
4
4
Payables & Accruals
2
1
2
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
267.73%
46.64%
Free Cash Flow
- -
565.24%
114.29%
Net Income, GAAP
- -
383.79%
41.8%
Sales/Revenue/Turnover
- -
- -
-32.1%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
1
2021
- -
- -
- -
- -
1
2022
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
-0.01
- -
- -
- -
-0.01
2021
- -
- -
- -
- -
-0.02
2022
- -
0.02
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Similar Companies
Norris Medicines Limited (NORRIS.BO)
Trees Corporation (TREE.NE)
VIA Pharmaceuticals, Inc. (VIAP)
Atara Biotherapeutics Inc (0HIY.L)
Sugi Holdings Co.,Ltd. (SGIPF)
TG Therapeutics, Inc. (0VGI.L)
Business
EastWest Bioscience Inc. (TSXV:EAST, OTCQB:HBOSF) operates as a vertically integrated wellness company focused on the manufacture, marketing, and distribution of hemp-based nutritional products and natural health supplements for humans and pets. The company offers core products including hemp-derived CBD items such as tinctures, creams, salves, and bulk CBD; natural biopharmaceutical health supplements under the Natural Advancement brand; pet nutrition products under the Natural Pet Science brand; and additional consumer lines like Earth's Menu and other nutraceuticals encompassing vitamins, minerals, herbs, proteins, and organic body care items, with custom blending, co-packing, and production services through its Health Canada-licensed, GMP-certified manufacturing facility. It serves retail chains, distributors, and consumers targeting preventive health lifestyles. Founded in 2016 and headquartered in Penticton, British Columbia, Canada, with prior operations linked to Richmond, British Columbia, EastWest Bioscience conducts business primarily in Canada and the United States, with distribution extending to New Zealand, Australia, and Asia. Recent developments include the grant of stock options and debt settlements to support operations as of 2021-2022 filings; a mortgage financing maturing December 31, 2025; and ongoing pursuits of processor, analytical, research licenses via joint venture intent with Benchmark Botanicals, alongside US joint ventures with Azema Sciences for CBD supply and distribution partnerships like Rise North America, positioning the company for expanded hemp and CBD market penetration.

Company News

APIChatGPT

  • accesswire.com

    EastWest Bioscience Announces Shares for Debt Settlement

  • accesswire.com

    EastWest Bioscience Announces Grant of Options and Debt Settlement

  • accesswire.com

    Eastwest Announces Resignation of CFO and Appointment of Interim CFO